@cashflow_king94 Absolutely. Invested on a thesis, thesis changed so got out ASAP. Sticking with ETFs unless something catches my mind. Means I'm not obsessing on checking single stocks daily just checking the wider market for dips caused by Trump 🤣.
@CxllumJxmes03 Fees for me. But I do have a Vanguard account to for their lifestrategy funds not available via ETF and because its more boring for my regular monthly investments I've been doing for years 🤣
@cashflow_king94 Agree even in the past education trumps advice. I always remember my dad paying for advice just to be told he was doing everything right and this was 10+ years ago. You need to do your own research even with advice too!
@cashflow_king94 Subbed! Very early on with an income portfolio fancied a bit of diversification vs all world ETF. 75% in different bond funds and 25% in JEQP all dividends reinventing 🤣 not really sure what I'm doing but will catch a few videos.
I've been breaking down my full investing strategy on YouTube.
How I built from £0.
The Ultimate Monthly Income Pie.
The new Growth Pie.
Options strategies.
ISA vs Taxable. All of it.
If you're following me here you'll get even more value from the channel. Longer breakdowns. Screen recordings. Full walkthroughs.
Hit subscribe if you haven't already.
New videos dropping every week.
Link in my Profile Bio.
@2147mill Not sure why there's so much hate under here. Employer matching is unbeatable even without the other tax benefits! Always take the max affordable if employer offers matching 💯
There's 5 modules to a BLA dossier so I assume they are excluding admin info section 🤔 but as expected CMC is the rate limiting step. Duration of effect critical to gaining price power too so interesting note of no guidance on 2 year data $SGMO https://t.co/GYTMdQlFOD
Jefferies $SGMO cont. discussions w/
partners to finalize Fabry deal
pharma interest at world
become more valuable as advances through regulatory process/
derisking ahead (BLA accept to review)
which should put some pressure on partner
convos
submit 3 out of 4 modules this month
@yachmod@douglas_ingram Share price wont react massively until 2 or 3 quarters of consistent Elevidys sales at whatever the "powers that be" deem acceptable. Newsflow will be critical to short term e.g. results from siRNA phase 1/2 but even this is secondary to seeing Elevidys sales IMO
Watching the $HIMS GLP-1 story. I always thought FDA would take action at some point as per risks, will be interesting if we see it played out in court. Will be a regulatory case study for years!